Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Oncotech Inc
Profile last edited on: 1/24/08      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1986
First Award
1986
Latest Award
2002
Program Status
Inactive (Acquired)
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

15501 Red Hill Avenue
Tustin, CA 92780
   (714) 566-0420
   drugdevelopment@oncotech.com
   www.oncotech.com
Location: Single
Congr. District: 45
County: Orange

Public Profile

In November of 2007, Oncotech Inc was acquired by Exiqon A/S of Denmark. Oncotech is dedicated to improving the survival and quality of life of cancer patients through its molecular oncology testing services as well as through genomic research leading to the discovery and development of new diagnostic and pharmaceutical products. Oncotech provides innovative molecular oncology testing services to over one thousand hospitals throughout the United States and Europe to assist physicians in the care and management of their cancer patients. Oncotech is a market leader in the field of in vitro drug resistance and therapy selection testing.

Extent of SBIR involvement

User Avatar
Phase I Awards
5
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$349,354
Phase II Dollars
$0
Total Awarded
$349,354

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2002 1 NIH $99,701
Project Title: Genomics Screening for Antiangiogenesis Drugs
2001 1 NIH $99,653
Project Title: A New High Throughput Assay for Human MDR1 Substrates
1993 1 NIH $50,000
Project Title: Development of therapeutic TNF degardation product
1993 1 NIH $50,000
Project Title: Development of an MDR-1 resistance reversal assay
1986 1 NIH $50,000
Project Title: Detection and circumventation of drug resistance

Key People / Management

  Frank Kiesner -- President

  John P Fruehauf

  Eugene Mechetner

  Robert A Nagourney

Company News

There are no news available.